The clinical efficacy of two intensive treatment packages (one including the new antipsychotic risperidone and the other not doing so) was compared with that of standard management in 43 patients with long-standing treatment-resistant schizophrenia. Significant differences between the groups in terms of total positive or total negative symptoms were not demonstrated, but the pattern of change between the treatment groups differed, so that benefit in positive symptomatology was seen in both intensive treatment groups and in negative symptomatology in the intensive treatment/risperidone group and the standard group. Changes in general psychopathology were most marked in the risperidone group and were compatible with a relatively non-sedative profile. Using the Disability Assessment Schedule, substantial significant advantages for the intensive treatment groups were found.
American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders (DSM-III-R) . American Psychiatric Association, Washington DC
2.
Borison R.L., Pathiraja A.P., Diamond B.I., Meibach R.C. (1992) Risperidone: clinical safety and efficacy in schizophrenia . Psychopharmac Bull28: 213-218
3.
Chouinard G., Jones B., Remington G., Bloom D., Addington D., McEwan G.W., Labelle A., Beuclair L., Arnott W. (1993) A Canadian multi-centre placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenia patients. J Clin Psychopharmac13: 25-40
4.
Davis J.M. (1976) Recent developments in the drug treatment of schizophrenia . Am J Psychiat133: 208-214
5.
Dencker S.J., May Pra (1988) From chronic mental hospital care to integration into society. In Dencker S J, Kulhanek F (eds), Treatment resistance in schizophrenia. Vieweg, Braunschweig , pp. 13-21
6.
Feighner J.P., Robins E., Guze S., Woodruff R.A. Jnr, Winokur G., Munoz R. (1972) Diagnostic criteria for use in psychiatric research . Archs Gen Psychiat26: 57-62
7.
Foster P. (1989) Neuroleptic equivalence. Pharmaceut J243: 431-432
8.
Guy W. ( 1976) Abnormal involuntary movements scale (AIMS). In ECDU assessment manual. Department of Health Education and Welfare, Rockville, MD
9.
Jablensky A., Schwaltz R., Tomov T. (1980) WHO collaborative study on impairments and disabilities associated with schizophrenic disorders. A preliminary communication: objectives and methods. Acta Psychiat Scand62 (Suppl. 285):152-163
Kane J., Honigfeld G., Singer J., Meltzer H. and the Clozaril Collaborative Study Group (1988) Clozapine for the treatment-resistant schizophrenic: a double blind comparison versus chlorpromazine/benztropine. Archs Gen Psychiat45: 789-796
12.
Kane J.M., McGlashan T.H. (1995) Treatment of schizophrenia. Lancet346: 820-825
13.
Kay S.R., Fiszbein A., Opler L.A. (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull13/2: 261-276
14.
Liberman R.P. (1982) Assessment of social skills. Schizophr Bull8: 63-83
15.
Lingjaerde O., Ahlfors UG, Bech P., Dencker S.J., Elgen K. (1987) The UKU side effect rating scale. Acta Psychiat Scand76 (Suppl. 334)
16.
Macmillan J.F., Crow TJ, Johnson A.L., Johnstone E.C. (1986) The Northwick Park study of first episodes of schizophrenia. III: Short term outcome in trial entrants and trial eligible patients. Br J Psychiat148: 128-133
17.
Marder S.R., Meibach R.C. (1994) Risperidone in the treatment of schizophrenia. Am J Psychiat151: 825-835
18.
May Pra, Dencker S.J., Hubbard J.W., Midha K.K., Liberman R.P. (1988) A systematic approach to treatment resistance in schizophrenic disorders. In Dencker S J, Kulhanek F (eds), Treatment resistance in schizophrenia. Vieweg, Braunschweig
19.
Morrison R.L., Bellack AS (1987) Social functioning of schizophrenic patients: clinical and research issues. Schizophr Bull13: 715-725
20.
National Institute of Mental Health (1964) Psychopharmacology Service Center, Collaborative Study Group. Phenothiazine treatment in acute schizophrenia: effectiveness. Archs Gen Psychiat10: 246-261
21.
Owens D G C (1996) Adverse effects of antipsychotic agents—do newer agents offer advantages?Drugs51: 895-930
22.
Owens D G C, Finlayson A., Mercer G., Johnstone E.C. (1997) The use of videotaped assessment in relation to a study of enhanced management in treatment-resistant schizophrenia. J Psychopharmac11: 357-360
23.
Peuskens J. on behalf of the Risperidone Study Group (1995) Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiat166: 712-726
24.
Schulz P., Rey M-J., Dick P.,Tissot R. (1989) Guidelines for the dosage of neuroleptics II: Changing from daily oral to long acting injectable neuroleptics. Int Clin Psychopharmac4:105-114
25.
Simpson G.W., Levinson D.F. (1988) Can we increase the response to somatic therapies for schizophrenia? In Dencker S J, Kulhanek F (eds), Treatment resistance in schizophrenia. Vieweg, Braunschweig
26.
Tuma A.H., May P R A (1979) And if that doesn't work, what next? A study of treatment failures in schizophrenia. J Nerv Ment Dis167: 566-571
27.
Wojcik J.D., Gelenberg A.J., Labrie R.A., Mieske M. (1980) Prevalence of tardive dyskinesia in an outpatient population. Comp Psychiat21: 370-380
